Used in targeted cancer therapies, particularly for non-small cell lung cancer, colorectal cancer, and head and neck cancers where EGFR is overexpressed. Binds specifically to the extracellular domain of EGFR, blocking ligand binding and inhibiting downstream signaling pathways involved in cell proliferation and survival. Employed as a reference in immunoassays, flow cytometry, and immunohistochemistry to detect EGFR expression in tumor tissues. Supports development and quality control of biosimilars and new anti-EGFR therapeutics. Also utilized in preclinical research to study EGFR internalization, receptor dynamics, and mechanisms of drug resistance.